Imagine a stroke as a plumbing blockage in the brain that causes a fire of inflammation, destroying healthy cells. This technology acts like a specialized fire extinguisher that targets a specific protein to stop that damage. It works alongside existing clot-removing treatments to save more brain tissue and help patients recover their independence.
Current stroke treatments have a very narrow time window and strict eligibility, leaving 80% of patients without effective options. Existing neuroprotectants have failed to show enough efficacy to gain regulatory approval.
An aptamer-based neuroprotectant drug (ApTOLL) that targets the TLR4 receptor to reduce brain inflammation and damage.
If you are a drug developer dealing with the high failure rate of neuroprotectants — this project developed ApTOLL that reduced mortality from 18% to 4%. It uses an aptamer to target the TLR4 receptor, offering a new way to enter the stroke management market.
If you are a hospital dealing with the fact that only 20% of patients are eligible for current reperfusion treatments — this project developed a neuroprotectant that improves functional outcomes. It is designed to be used in combination with endovascular therapy to reduce brain damage.
If you are a biotech firm dealing with the challenge of delivering effective brain-targeting molecules — this project developed an aptamer-based therapy. It demonstrates a 47% reduction of FIV in acute ischemic stroke patients.
Based on available project data, the specific price per dose is not mentioned, but the global cost of stroke is noted as >€847b.
Yes, the project has focused on the optimization of the manufacturing process to facilitate market access.
AptaTargets has already signed a transaction with a big pharma company to take the product to market and launch trials for other indications.
The project period runs from 2024-01-01 to 2026-03-31, with the goal of completing Ph2b trials before entering Ph3.
ApTOLL is designed to be used in combination with endovascular therapy (EVT) during the acute phase of a stroke.
The project is led by a single Spanish SME, AptaTargets SL, which holds 100% of the industry ratio. This lean structure allowed the company to rapidly move from preclinical stages to a Phase II trial and successfully secure a licensing deal with a global pharmaceutical company.
Contact AptaTargets SL in Spain regarding the ApTOLL-AIS program.
Contact us to explore licensing opportunities for aptamer-based neuroprotectants.
